Heidi T. May

Heidi T. May

Auto-generated profile, based on publicly available information

Heidi T. May

Intermountain Medical Center Heart Institute Cardiovascular Research 5121 S. Cottonwood Street, Salt Lake City, UT 84107

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2007 in Circulation
Verified
Journal Article
Open access
PDF file
JAJeffrey L. Anderson
Jeffrey L. Anderson
BHBenjamin D. Horne
Benjamin D. Horne
SSScott M. Stevens
Scott M. Stevens
AGAmanda S. Grove
Amanda S. Grove
SBStephanie Barton
Stephanie Barton
JCJohn F. Carlquist
John F. Carlquist
Background— Pharmacogenetic-guided dosing of warfarin is a promising application of “personalized medicine” but has not been adequately tested in randomized trials. Methods and Results— Consenting patients (n=206) being initiated on warfarin were randomized to pharmacogenetic-guided or standard dosing. Buccal swab DNA was genotyped for CYP2C9 *2 and CYP2C9 * 3 and VKORC1 C1173T with a rapid assay. Standard dosing followed an empirical protocol, whereas pharmacogenetic-guided dosing followed a regression equation including the 3 genetic variants and age, sex, and weight. Prothrombin time international normalized ratio (INR) was measured routinely on days 0, 3, 5, 8, 21, 60, and 90. A research pharmacist unblinded to treatment strategy managed dose adjustments. Patients were followed up for up to 3 months. Pharmacogenetic-guided predicted doses more accurately approximated stable doses ( P <0.001), resulting in smaller ( P =0.002) and fewer ( P =0.03) dosing changes and INRs ( P =0.06). However, percent out-of-range INRs (pharmacogenetic=30.7%, standard=33.1%), the primary end point, did not differ significantly between arms. Despite this, when restricted to wild-type patients (who required larger doses; P =0.001) and multiple variant carriers (who required smaller doses; P <0.001) in exploratory analyses, results (pharmacogenetic=29%, standard=39%) achieved nominal significance ( P =0.03). Multiple variant allele carriers were at increased risk of an INR of ≥4 ( P =0.03). Conclusions— An algorithm guided by pharmacogenetic and clinical factors improved the accuracy and efficiency of warfarin dose initiation. Despite this, the primary end point of a reduction in out-of-range INRs was not achieved. In subset analyses, pharmacogenetic guidance showed promise for wild-type and multiple variant genotypes.

1 October 2010 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JAJeffrey L. Anderson
Jeffrey L. Anderson
HMHeidi T. May
Heidi T. May
BHBenjamin D. Horne
Benjamin D. Horne
TBTami L. Bair
Tami L. Bair
NHNathaniel L. Hall
Nathaniel L. Hall
JMJoseph B. Muhlestein
Joseph B. Muhlestein

1 November 2012 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
LWLu Wang
Lu Wang
YSYiqing Song
Yiqing Song
JMJoAnn E. Manson
JoAnn E. Manson
Stefan PilzStefan Pilz
Stefan Pilz
WMWinfried März
Winfried März
HSHoward D. Sesso
Howard D. Sesso
Background—: Vitamin D status has been linked to the risk of cardiovascular disease (CVD). However, the optimal 25-hydroxy-vitamin D (25[OH]-vitamin D) levels for potential cardiovascular health benefits remain unclear. Methods and Results—: We searched MEDLINE and EMBASE from 1966 through February 2012 for prospective studies that assessed the association of 25(OH)-vitamin D concentrations with CVD risk. A total of 24 articles met our inclusion criteria, from which 19 independent studies with 6123 CVD cases in 65 994 participants were included for a meta-analysis. In a comparison of the lowest with the highest 25(OH)-vitamin D categories, the pooled relative risk was 1.52 (95% confidence interval, 1.30–1.77) for total CVD, 1.42 (95% confidence interval, 1.19–1.71) for CVD mortality, 1.38 (95% confidence interval, 1.21–1.57) for coronary heart disease, and 1.64 (95% confidence interval, 1.27–2.10) for stroke. These associations remained strong and significant when analyses were limited to studies that excluded participants with baseline CVD and were better controlled for season and confounding. We used a fractional polynomial spline regression analysis to assess the linearity of dose–response association between continuous 25(OH)-vitamin D and CVD risk. The CVD risk increased monotonically across decreasing 25(OH)-vitamin D below ≈60 nmol/L, with a relative risk of 1.03 (95% confidence interval, 1.00–1.06) per 25-nmol/L decrement in 25(OH)-vitamin D. Conclusions—: This meta-analysis demonstrated a generally linear, inverse association between circulating 25(OH)-vitamin D ranging from 20 to 60 nmol/L and risk of CVD. Further research is needed to clarify the association of 25(OH)-vitamin D higher than 60 nmol/L with CVD risk and assess causality of the observed associations.

5 December 2006 in Circulation
Verified
Journal Article
Closed access
PDF file
CIC. Arden Pope III
C. Arden Pope III
JMJoseph B. Muhlestein
Joseph B. Muhlestein
HMHeidi T. May
Heidi T. May
DRDale G. Renlund
Dale G. Renlund
JAJeffrey L. Anderson
Jeffrey L. Anderson
BHBenjamin D. Horne
Benjamin D. Horne
Background— Recent evidence suggests that long-term exposure to particulate air pollution contributes to pulmonary and systemic oxidative stress, inflammation, progression of atherosclerosis, and risk of ischemic heart disease and death. Short-term exposure may contribute to complications of atherosclerosis, such as plaque vulnerability, thrombosis, and acute ischemic events. These findings are inconclusive and controversial and require further study. This study evaluates the role of short-term particulate exposure in triggering acute ischemic heart disease events. Methods and Results— A case-crossover study design was used to analyze ischemic events in 12 865 patients who lived on the Wasatch Front in Utah. Patients were drawn from the cardiac catheterization registry of the Intermountain Heart Collaborative Study, a large, ongoing registry of patients who underwent coronary arteriography and were followed up longitudinally. Ambient fine particulate pollution (particles with an aerodynamic diameter ≤2.5 μm; PM 2.5 ) elevated by 10 μg/m 3 was associated with increased risk of acute ischemic coronary events (unstable angina and myocardial infarction) equal to 4.5% (95% confidence interval, 1.1 to 8.0). Effects were larger for those with angiographically demonstrated coronary artery disease. Conclusions— Short-term particulate exposures contributed to acute coronary events, especially among patients with underlying coronary artery disease. Individuals with stable presentation and those with angiographically demonstrated clean coronaries are not as susceptible to short-term particulate exposure.

29 August 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff
DBDeepak L Bhatt
Deepak L Bhatt
AKApril Kinninger
April Kinninger
SLSuvasini Lakshmanan
Suvasini Lakshmanan
JMJoseph B Muhlestein
Joseph B Muhlestein
JNJohn R Nelson
John R Nelson
Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a statin was shown to reduce initial CV events by 25% and total CV events by 32% in the REDUCE-IT trial, with the mechanisms of benefit not yet fully explained. The EVAPORATE trial sought to determine whether IPE 4 g/day, as an adjunct to diet and statin therapy, would result in a greater change from baseline in plaque volume, measured by serial multidetector computed tomography (MDCT), than placebo in statin-treated patients. A total of 80 patients were enrolled in this randomized, double-blind, placebo-controlled trial. Patients had to have coronary atherosclerosis as documented by MDCT (one or more angiographic stenoses with ≥20% narrowing), be on statin therapy, and have persistently elevated triglyceride (TG) levels. Patients underwent an interim scan at 9 months and a final scan at 18 months with coronary computed tomographic angiography. The pre-specified primary endpoint was change in low-attenuation plaque (LAP) volume at 18 months between IPE and placebo groups. Baseline demographics, vitals, and laboratory results were not significantly different between the IPE and placebo groups; the median TG level was 259.1 ± 78.1 mg/dL. There was a significant reduction in the primary endpoint as IPE reduced LAP plaque volume by 17%, while in the placebo group LAP plaque volume more than doubled (+109%) (P = 0.0061). There were significant differences in rates of progression between IPE and placebo at study end involving other plaque volumes including fibrous, and fibrofatty (FF) plaque volumes which regressed in the IPE group and progressed in the placebo group (P < 0.01 for all). When further adjusted for age, sex, diabetes status, hypertension, and baseline TG, plaque volume changes between groups remained significantly different, P < 0.01. Only dense calcium did not show a significant difference between groups in multivariable modelling (P = 0.053). Icosapent ethyl demonstrated significant regression of LAP volume on MDCT compared with placebo over 18 months. EVAPORATE provides important mechanistic data on plaque characteristics that may have relevance to the REDUCE-IT results and clinical use of IPE.

1 April 2010 in Heart Rhythm
Verified
Journal Article
Closed access
TBThomas Jared Bunch
Thomas Jared Bunch
JWJ. Peter Weiss
J. Peter Weiss
BCBrian G. Crandall
Brian G. Crandall
HMHeidi T. May
Heidi T. May
TBTami L. Bair
Tami L. Bair
JDJohn D. Day
John D. Day